Goulart Isabela Maria Bernades, Arbex Guilherme Leonel, Carneiro Marcus Hubaide, Rodrigues Mariana Scalia, Gadia Rafael
Departamento de Clínica Médica da Faculdade de Medicina da Universidade Federal de Uberlândia, Uberlândia, MG.
Rev Soc Bras Med Trop. 2002 Sep-Oct;35(5):453-60. doi: 10.1590/s0037-86822002000500005. Epub 2002 Nov 29.
The introduction of multidrug therapy (WHO/MDT)-composed by the drugs dapsone, clofazimine and rifampicin has enabled the cure of Hansen's disease, however, the adverse effects of these drugs were not given priority by the health team. Aiming to determine MDT's adverse effects' magnitude and relate them to the non-adhesion of patients to the treatment, a study of 187 charts of patients treated with MDT from January of 1995 to May 2000, was carried out at a Health Center of the Federal University of Uberlândia. Side effects were recorded in 71 patients' charts. Among the 113 side effects found, 80 (70.7%) were related to dapsone, 7 (6.2%) were caused by rifampicin and 26 (20.5%) were attributed to clofazimine. These effects induced 28 (14.9%), patients to change the therapeutic scheme, representing 39.4% from the 71 patients with adverse effects. Throughout this study, the importance is discussed of considering MDT's adverse effects when training the health team to heighten the patient's adhesion to the treatment and thereby collaborating to eliminate Hansen's disease as a public health problem.
由氨苯砜、氯法齐明和利福平组成的多药联合疗法（世卫组织/MDT）的引入，使麻风病得以治愈，然而，这些药物的不良反应未受到卫生团队的重视。为了确定多药联合疗法不良反应的严重程度，并将其与患者不坚持治疗的情况联系起来，乌贝兰迪亚联邦大学的一个健康中心对1995年1月至2000年5月期间接受多药联合疗法治疗的187例患者的病历进行了一项研究。在71例患者的病历中记录了副作用。在发现的113例副作用中，80例（70.7%）与氨苯砜有关，7例（6.2%）由利福平引起，26例（20.5%）归因于氯法齐明。这些副作用导致28例（14.9%）患者改变治疗方案，占71例有不良反应患者的39.4%。在整个研究过程中，讨论了在培训卫生团队时考虑多药联合疗法不良反应的重要性，以提高患者对治疗的依从性，从而协助消除作为公共卫生问题的麻风病。
